FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing
FV-162 是一种新型的、口服生物利用度高的、不可逆的蛋白酶体抑制剂,具有改进的药代动力学,在临床前研究中显示出每日持续给药的疗效。
期刊:Cell Death & Disease
影响因子:9.6
doi:10.1038/cddis.2015.187
Wang, Z; Dove, P; Wang, X; Shamas-Din, A; Li, Z; Nachman, A; Oh, Y J; Hurren, R; Ruschak, A; Climie, S; Press, B; Griffin, C; Undzys, E; Aman, A; Al-awar, R; Kay, L E; O'Neill, D; Trudel, S; Slassi, M; Schimmer, A D